Efficacy and Safety of Meteospasmyl® in Irritable Bowel Syndrome

• Status: Completed
• Trial end date: 2008-09-01
• Target enrollment: 0
• Participant gender: All

Summary

To assess the effectiveness of alverine citrate and simeticone on IBS symptoms according to the latest recommended design

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Laboratoires Mayoly Spindler
• Treatments: Alverine; Mebeverine

Criteria

Inclusion Criteria:

• male or female ambulatory patients, aged 18-75 years

• with IBS as defined by Rome III criteria

Exclusion Criteria:

• Functional bowel disorder other than IBS,

• Underlying cause for symptomatology, which excludes IBS diagnosis,

• Gastro-intestinal cancer or significant gastro-intestinal surgical background,

• Any acute/uncontrolled systemic pathology